One could assume the possibility of increased 90-day survival for patients with septic shock, as suggested by the ALBIOS post hoc analysis. The ALBIOS data do not indicate how much albumin was received by patients with septic shock; the data indicate the amount taken by all patients with sepsis and only for the first 7 days of treatment. The median volume of albumin was 1,100 mL. Using our cost of $82 for 100 mL of 25% albumin as a guide, this approach in the United States would add a median cost of $902 per case of septic shock (in the first 7 days). The median volume of crystalloid in the albumin group was reduced by 2 L, reducing the bill by approximately $3. The post hoc analysis suggested an absolute reduction in 90-day mortality of 6.6% in the albumin group, indicating a number-needed-to-treat of 16 patients per additional life saved. The additional critical care cost per life saved would then be $14,384, a reasonable cost, on the order of an annual mammography, bone marrow transplant vs chemotherapy for acute myeloid leukemia, or beta-blocker for postmyocardial infarction risk reduction. However—and this is a huge however—the calculation depends on the reliability of the data, and it cannot be overemphasized that the data are from an unplanned, post hoc analysis, which the trial was not designed to address. The ALBIOS trial was itself based on such an analysis of the SAFE trial, and one readily sees where that has brought us.